Fixed-dose combination
Epinephrine and Lidocaine is a fixed-dose combination of an amide local anesthetic, an antiarrhythmic and a catecholamine. It is available as injection for infiltration, perineural and submucosal use. MedsAcross supplies Epinephrine and Lidocaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Xylocaine (lidocaine HCl) Injections are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
Source: US FDA prescribing information
Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Source: US FDA prescribing information
Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Xylocaine Injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated. There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Xylocaine is not approved for this use. These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures.
Source: US FDA prescribing information
Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.
Source: US FDA prescribing information
XYLOCAINE INJECTIONS FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES. DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use.
Source: US FDA prescribing information
Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.
Source: US FDA prescribing information
Xylocaine® (lidocaine HCl Injection, USP) Product Code Unit of Sale Strength Each PRX480527 NDC 63323-485-26 Unit of 25 1% 200 mg per 20 mL (10 mg per mL) NDC 63323-485-41 20 mL Multiple Dose Vial PRX480627 NDC 63323-486-26 Unit of 25 2% 400 mg per 20 mL (20 mg per mL) NDC 63323-486-41 20 mL Multiple Dose Vial Xylocaine® -MPF (lidocaine HCl Injection, USP) Product Code Unit of Sale Strength Each PRX491227 NDC 63323-492-16 Unit of 25 1% 20 mg per 2 mL (10 mg per mL) NDC 63323-492-41 2 mL Single Dose Vial PRX491257 NDC 63323-492-36 Unit of 25 1% 50 mg per 5 mL (10 mg per mL) NDC 63323-492-43 5 mL Single Dose Vial PRX491237 NDC 63323-492-26 Unit of 25 1% 300 mg per 30 mL (10 mg per mL) NDC…
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
38 presentations of Epinephrine and Lidocaine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Epinephrine and Lidocaine 0.017 mg/34 mg per 1.7 mL injectionSubmucosalGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 0.034 mg/34 mg per 1.7 mL injectionSubmucosalGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 500 mcg/1000 mg per 50 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 200 mcg/200 mg per 20 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 200 mcg/400 mg per 20 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Xylocaine 0.2 mg/200 mg per 20 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine 0.5 mg/500 mg per 50 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Epinephrine and Lidocaine 300 mcg/600 mg per 30 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 500 mcg/500 mg per 50 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Xylocaine 0.2 mg/400 mg per 20 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Epinephrine and Lidocaine 0.1 mg/400 mg per 20 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 25 mcg/75 mg per 5 mL injectionEpiduralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 250 mcg/250 mg per 50 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Xylocaine 0.25 mg/250 mg per 50 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine 0.5 mg/1000 mg per 50 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Epinephrine and Lidocaine 0.05 mg/200 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 0.15 mg/300 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 10 mcg/10 mg per 1 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Xylocaine MPF 0.1 mg/400 mg per 20 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine MPF 0.15 mg/300 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine MPF 0.15 mg/450 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Epinephrine and Lidocaine 0.025 mg/75 mg per 5 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 0.1 mg/100 mg per 10 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 10 mcg/20 mg per 1 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 150 mcg/450 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 300 mcg/300 mg per 30 mL injectionInfiltrationGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 300 mcg/300 mg per 30 mL injectionInfiltration, perineuralGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Epinephrine and Lidocaine 500 mcg/500 mg per 50 mL injectionInfiltrationGeneric name | Epinephrine and Lidocaine | — | US FDA | Available on request |
| Flavalta 0.017 mg/34 mg per 1.7 mL injectionSubmucosal | Epinephrine and Lidocaine | Septodont | US FDA | Available on request |
| Lignospan Forte 0.034 mg/34 mg per 1.7 mL injectionSubmucosal | Epinephrine and Lidocaine | Septodont | US FDA | Available on request |
| Lignospan Standard 0.017 mg/34 mg per 1.7 mL injectionSubmucosal | Epinephrine and Lidocaine | Septodont | US FDA | Available on request |
| Xylocaine 0.1 mg/100 mg per 10 mL injectionInfiltration, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine 0.1 mg/400 mg per 20 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Henry Schein | US FDA | Available on request |
| Xylocaine 17 mcg/34 mg per 1.7 mL injectionSubmucosal | Epinephrine and Lidocaine | Dentsply Pharmaceutical | US FDA | Available on request |
| Xylocaine 34 mcg/34 mg per 1.7 mL injectionSubmucosal | Epinephrine and Lidocaine | Dentsply Pharmaceutical | US FDA | Available on request |
| Xylocaine MPF 0.05 mg/100 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine MPF 0.05 mg/150 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
| Xylocaine MPF 0.05 mg/200 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineural | Epinephrine and Lidocaine | Fresenius Kabi | US FDA | Available on request |
5 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 19 November 1948 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Epinephrine and Lidocaine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 38 presentations of Epinephrine and Lidocaine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 5 brand names for Epinephrine and Lidocaine, including Flavalta, Lignospan Forte, Lignospan Standard, Xylocaine, Xylocaine MPF.
Yes. The US FDA first approved Epinephrine and Lidocaine on 19 November 1948, according to Drugs@FDA.
No listed presentation of Epinephrine and Lidocaine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.